Log in

Antisense Therapeutics Limited (ANP.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$0.05
52-Week Range N/A
Volume1.32 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 3 9827 8999



Sales & Book Value

Annual Sales$668,433.00
Book ValueA$0.01 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive ANP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Antisense Therapeutics Limited (ANP.AX) (ASX:ANP) Frequently Asked Questions

What stocks does MarketBeat like better than Antisense Therapeutics Limited (ANP.AX)?

Wall Street analysts have given Antisense Therapeutics Limited (ANP.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antisense Therapeutics Limited (ANP.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Antisense Therapeutics Limited (ANP.AX)'s earnings last quarter?

Antisense Therapeutics Limited (ANP.AX) (ASX:ANP) issued its quarterly earnings results on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter.
View Antisense Therapeutics Limited (ANP.AX)'s earnings history

Who are some of Antisense Therapeutics Limited (ANP.AX)'s key competitors?

What other stocks do shareholders of Antisense Therapeutics Limited (ANP.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antisense Therapeutics Limited (ANP.AX) investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN).

Who are Antisense Therapeutics Limited (ANP.AX)'s key executives?

Antisense Therapeutics Limited (ANP.AX)'s management team includes the following people:
  • Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD, CEO, MD & Director
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 61, Pay $99k)

What is Antisense Therapeutics Limited (ANP.AX)'s stock symbol?

Antisense Therapeutics Limited (ANP.AX) trades on the ASX under the ticker symbol "ANP."

How big of a company is Antisense Therapeutics Limited (ANP.AX)?

Antisense Therapeutics Limited (ANP.AX) has a market capitalization of $0.00 and generates $668,433.00 in revenue each year. Antisense Therapeutics Limited (ANP.AX) employs 8 workers across the globe.

What is Antisense Therapeutics Limited (ANP.AX)'s official website?

The official website for Antisense Therapeutics Limited (ANP.AX) is www.antisense.com.au.

How can I contact Antisense Therapeutics Limited (ANP.AX)?

The company can be reached via phone at 61 3 9827 8999.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.